Similar to what was observed for ibrutinib, acquired resistance to acalabrutinib also resulted in overexpression of these miRNAs in CLL and DLBCL cells and downregulation of PTEN, revealing aberrant expression of 14q32 cluster miRNAs as a common mechanism of resistance to BTK inhibition. The gene discussed is BTK; the disease is diffuse large B-cell lymphoma.